Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad26.Mos.HIV + MVA-Mosaic
- Development stage
- Discontinued
- Lead developer
- Janssen Pharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ad26.Mos.HIV + MVA-Mosaic is a heterologous prime-boost HIV-1 vaccine regimen developed by Janssen (Johnson & Johnson). The regimen utilizes two distinct viral vectors: a recombinant adenovirus serotype 26 (Ad26.Mos.HIV) and a modified vaccinia Ankara (MVA-Mosaic) vector. Both components are engineered to express 'mosaic' HIV-1 antigens—bioinformatically optimized sequences of Gag, Pol, and Env proteins designed to elicit broad immune responses against the high genetic diversity of global HIV-1 strains. While the regimen demonstrated robust immunogenicity in early-phase trials (APPROACH, TRAVERSE), large-scale efficacy trials for HIV prevention, including the Phase 2b IMBOKODO study and the Phase 3 MOSAICO study, were terminated after data indicated the vaccine did not provide sufficient protection against HIV infection. It has also been investigated as a therapeutic vaccine component in people living with HIV.
- Other names
- Mosaic HIV-1 vaccineJanssen HIV vaccine regimenMosaic HIV-1 vaccine regimen
02
Targets
Human immunodeficiency virus type 1 reverse transcriptasegp41 (Human immunodeficiency virus type 1 glycoprotein 41)Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on Ad26.Mos.HIV + MVA-Mosaic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad26.Mos.HIV + MVA-Mosaic.